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Pulmonary embolism is more prevalent 
than deep vein thrombosis in cases of chronic 




Background: Chronic lung diseases may have an influence on pulmonary vessel walls as well as on pulmonary 
haemodynamics. However, there is limited data on the occurrence of pulmonary embolism (PE) and deep vein throm-
bosis (DVT) in patients with chronic lung diseases, which have the potential to contribute to the development of 
pulmonary vascular abnormalities. We aimed to explore the prevalence of PE and DVT in patients with COPD and ILD.
Methods: We evaluated the venous thromboembolism prevalence associated with COPD and ILD using Korean 
Health Insurance Review and Assessment Service (HIRA) data from January 2011 to December 2011. This database 
(HIRA-NPS-2011-0001) was created using random sampling of outpatients; 1,375,842 sample cases were collected, 
and 670,258 (age ≥40) cases were evaluated. Patients with COPD, ILDs, or CTD were identified using the International 
Classification of Disease-10 diagnostic codes.
Results: The PE prevalence rates per 100,000 persons for the study population with COPD, ILD, CTD, and the general 
population were 1185, 1746, 412, and 113, respectively, while the DVT prevalence for each group was 637, 582, 563, 
and 138, respectively.
Conclusions: PE prevalence was significantly higher than that of DVT in patients with COPD or ILDs, while the preva-
lence of PE was lower than that for DVT in the general population or in patients with CTD.
Keywords: Chronic obstructive pulmonary disease, Interstitial lung disease, Pulmonary embolism, Deep vein 
thrombosis, Prevalence
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Background
The pathogenesis of pulmonary embolism (PE) explained 
by deep venous thrombosis (DVT), develops in the lower 
extremities where clots may dislodge and travel through 
the inferior vena cava eventually lodging in the pulmo-
nary arteries (Elliott 1992). Small clots from the lower 
extremities may start to lyse immediately and may resolve 
without serious clinical deterioration.
According to Virchow, venous thrombosis can be 
explained by blood stagnation (stasis), hypercoagulability, 
and vascular endothelial damage (endothelial dysfunc-
tion) (Bagot and Arya 2008). Venous blood flow gen-
eration is partly contributed to by the contraction of the 
muscle. It is thought that the pulmonary artery is unlikely 
to experience vascular injury from external factors. How-
ever, chronic lung diseases such as chronic obstructive 
pulmonary disease (COPD) or interstitial lung disease 
(ILD) may have an effect on the pulmonary circulation. 
In addition to airway and lung parenchymal abnormali-
ties, COPD is also characterized by pulmonary vascular 
alterations, including medial wall thickening and mus-
cularization of nonmuscularized arterioles (Magee et al. 
1988; Wright et  al. 1992). There have been studies that 
have focused on the vascular abnormalities experienced 
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in ILDs, such as increased angiogenic chemokines, aber-
rant angiogenesis, and capillary endothelial abnormali-
ties (Keane et  al. 1997; Cosgrove et  al. 2004; Renzoni 
et al. 2003; Sakao et al. 2006).
Finally, the higher prevalence of pulmonary hyperten-
sion in patients with ILDs and COPD may contribute to 
increased vascular resistance of the pulmonary vascular 
beds as well as stagnation of blood flow (Chaouat et  al. 
2008; Behr and Ryu 2008). Therefore, we suspect that 
pulmonary vascular bed alterations may be involved in 
PE and lower extremity vein thrombosis epidemiology. 
We hypothesized that patients with chronic lung diseases 
involving pulmonary vascular beds would have a higher 
prevalence of PE rather than DVT. To test the hypoth-
esis, we investigated the prevalence of PE and DVT with 
chronic lung diseases and connective tissue disorders 
(CTDs) and within the general population.
Methods
Study subjects
This is a retrospective cohort study based on data col-
lected from the Korean Health Insurance Review and 
Assessment Service (HIRA) national database. HIRA is 
a government-affiliated organization that builds an accu-
rate claims review and is a quality assessment system for 
the National Health Insurance (NHI). The NHI is the only 
public medical insurance system operated by the Ministry 
of Health and Welfare in Korea (Kim 2010a, b). We evalu-
ated the prevalence of lung cancer associated with ILD 
and idiopathic pulmonary fibrosis (IPF) utilizing HIRA 
data from January 2011 to December 2011. The database 
(HIRA-NPS-2011-0001) was based on a stratified random 
sampling of outpatients from the whole population. How-
ever, data included both outpatients and inpatients health 
services utilization. However, data include both outpa-
tients and inpatients health services utilization. The data-
base (HIRA-NPS-2011-0001) was built with first medical 
claims of the patients during 2011 and followed up until 
December 2011. Extracting patients by stratification sys-
tem were based on gender, age range, as well as diagnos-
tic and prescription history. There were 1,375,842 sample 
cases and 670,258 of these (age ≥40) cases were evaluated. 
Patients with CTD, ILD, or COPD were identified based 
on the International Classification of Disease-10 (ICD-10) 
diagnostic codes. This study was approved by the insti-
tutional review board at Dongsan Hospital, Keimyung 
University School of Medicine. Consent was not obtained 
since the patient information was anonymized.
Case identification
Cases were included in the study based upon diagnostic 
and treatment evidence of ILDs and IPF. Each case was 
included both the diagnostic and procedure codes were 
identified simultaneously. Diagnosis interstitial lung dis-
ease was based on doctor’s clinical judgment based on 
chest radiographic findings. These processes were per-
formed automatically using a computer-based program. 
The ICD-10 diagnostic codes are used as a reference for 
the medical diagnosis of diseases and within the health 
insurance system. We used the J44 (ICD-10 code) for the 
obstructive pulmonary disease. The diagnosis of COPD 
was based on clinical findings and spirometry. The codes 
used for the identification of systemic CTDs were as fol-
lows: M05 for rheumatoid arthritis; M07 for psoriatic and 
enteropathic arthropathies; M30 for polyarteritis; M31 for 
other necrotizing vasculopathies; M32 for systemic lupus 
erythematosus; M33 for dermatopolymyositis; M34 for 
systemic sclerosis; M35 for other systemic involvement of 
connective tissue; and M45 for ankylosing spondylitis.
The codes used for DVT included I80.2 (DVT, not oth-
erwise specified [NOS]) and I80.3 (embolism or throm-
bosis of a lower extremity, NOS). The codes used for PE 
included I26 (pulmonary thromboembolism), I26.0 (PE 
with mention of acute cor pulmonale), and I26.9 (PE, 
NOS). The codes used for intra-abdominal thrombosis 
(IAT) included I81 (portal vein thrombosis), I82 (other 
venous embolism or thrombosis), I82.0 (Budd–Chiari 
syndrome), I82.2 (embolism or thrombosis of the vena 
cava), and I82.3 (embolism or thrombosis of the renal 
vein). The codes used for thrombosis, no specified site 
(TNSS) included I82.8 (embolism and thrombosis of 
other specified veins) and I82.9 [embolism of the vein, 
NOS, and thrombosis (vein), NOS]. Cases that were 
recorded as both DVT and PE we regarded as cases of 
PE. Venous thromboembolism was validated by simulta-
neous anticoagulation at the time of diagnosis.
Analysis
We counted the number of patients diagnosed with 
ILD, CTD, or COPD in 2011 and calculated the preva-
lence rate. Ninety-five percent confidence intervals 
(CIs) were calculated using the normal approximation 
to the binomial distribution. A χ2 test was used to com-
pare frequencies. P values <0.05 were considered sta-
tistically significant. We compared the lung cancer 
prevalence rates among the groups. All analyses were 
conducted using SAS version 9 (SAS Institute, Cary, NC, 
USA), and likelihood ratio tests were used for all tests of 
significance.
Results
Patients with ILDs, COPD, and controls
A total of 66  % patients with ILD and 56.3  % of COPD 
controls were men. The median ages of the patients 
with ILD and those of the COPD controls were 68 and 
69  years, respectively. Approximately 2.8  % of patients 
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with ILD and 2.3 % of COPD controls had a previous his-
tory of thromboembolism (Table 1). 
Venous thromboembolism prevalence in the groups
From the random samples obtained from the NHI 
database during 2011, there were 670,258 cases aged 
≥40 years from a total of 1,375,842. The number of CTD 
and COPD cases accounted for 1.14 and 2.37  % of the 
sample population, respectively (Table 2).
Deep veins thrombosis (DVT) was detected in 885 
(0.29  %) cases among those aged ≥40  years. The DVT 
prevalence was 135.3 per 100,000 individuals within 
the general population. The DVT prevalence in men 
with CTD was 746.6 per 100,000 individuals, which is 
approximately 5.3 times higher than the prevalence seen 
within the general population. In addition to CTD, the 
DVT prevalence in men with COPD and ILD was about 
5 and 3 times, respectively, higher than the prevalence 
seen in men within the general population. However, the 
PE prevalence was 11–15 times higher in patients with 
COPD and ILD compared to the general population. The 
PE prevalence for patients with CTD was 1/3–1/4 of that 
seen for COPD or ILD patients, while the prevalence of 
DVT was similar among patients with CTD, ILD, and 
COPD.
Deep vein thrombosis and pulmonary embolism 
prevalence among the groups
The odds ratios for DVT prevalence were similar 
among COPD, CTD, and ILD patients. However, the 
Table 1 Demographic and clinical characteristics of patients with connective tissue disorders, chronic obstructive pulmo-
nary disease, interstitial lung diseases, and the general population
Between January 2011 and December 2011. Summarized based on the diagnosis at the top of the list from the International Statistical Classification of Diseases and 
Related Health Problems, 10th edition (ICD-10) codes of respiratory diseases
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, CTD connective tissue disorder
Characteristic General population 
(n = 640,177), n (%)
ILD (n = 859),  
n (%)





 Male 299,599 (46.80) 570 (66.36) 8832 (56.30) 2105 (28.91)
 Female 340,578 (53.20) 289 (33.64) 6854 (43.70) 5175 (71.09)
Age
 Median (Q1, Q3) 53 (46, 63) 68 (59, 76) 69 (60, 76) 57 (49, 68)
 40–49 233,823 (36.52) 67 (7.80) 1195 (7.62) 1825 (25.07)
 50–59 195,737 (30.58) 161 (18.74) 2525 (16.10) 2235 (30.70)
 60–69 116,203 (18.15) 242 (28.17) 4251 (27.10) 1716 (23.57)
 70–79 70,120 (10.95) 276 (32.13) 5223 (33.30) 1193 (16.39)
 ≥80 24,294 (3.79) 113 (13.15) 2492 (15.89) 311 (4.27)
Respiratory disease (prevalence)
 Influenza and Pneumonia (J09–J14) 3665 (0.57) 18 (2.10) 221 (1.41) 87 (1.20)
 Bacterial Pneumonia (J15, J16) 6187 (0.97) 107 (12.46) 1183 (7.54) 115 (1.58)
 Active tuberculosis (A15) 1121 (0.18) 25 (2.91) 335 (2.14) 30 (0.41)
Co-morbidity (prevalence)
 Malignancy (C00–C97) 32,140 (5.02) 180 (20.95) 2623 (16.72) 529 (7.27)
 Diabetes (E10–E14) 108,639 (16.97) 309 (35.97) 5385 (34.33) 1894 (26.02)
 Chronic renal failure (N17–N19) 7662 (1.20) 50 (5.82) 723 (4.61) 191 (2.62)
 Previous myocardial infarction  
(I21, I22, I23, 25.2)
5983 (0.93) 35 (4.07) 578 (3.68) 114 (1.57)
 Congestive heart failure (I50) 9584 (1.50) 92 (10.71) 1551 (9.89) 186 (2.55)
 Varicose veins of lower extremities  
(I83, O22.0, O87.8)
3655 (0.57) 5 (0.58) 105 (0.67) 68 (0.93)
 Hospital admission 98,780 (15.43) 482 (56.11) 7100 (45.26) 1925 (26.44)
 Surgery 207,567 (32.42) 401 (46.68) 7141 (45.52) 2667 (36.63)
 Atrial fibrillation (I48) 6340 (0.99) 46 (5.36) 829 (5.28) 108 (1.48)
 Inflammatory bowel disease  
(N50–N52)
294 (0.05) 1 (0.12) 10 (0.06) 5 (0.07)
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PE prevalence in patients with COPD or ILD was sig-
nificantly higher than in patients with CTD (P  <  0.01) 
(Table 3).
Pulmonary embolism‑to‑deep vein thrombosis prevalence 
ratio among the groups
The PE-to-DVT prevalence ratio in the general popula-
tion was 0.78. The ratios for COPD, ILD, and CTE were 
1.8, 3.1, and 0.66, respectively. The prevalence of PE was 
the highest in patients with ILD (Fig. 1).
Discussion
This is a population-based study, which provides new 
data supporting the association of chronic lung diseases 
such as ILD and COPD with PE. The PE prevalence rates 
per 100,000 individuals from the study population with 
COPD, ILD, CTD without ILD, and the general popula-
tion were 1185, 1746, 412, and 113, respectively, while 
the DVT prevalence rates were 637, 582, 563, and 138, 
respectively. The prevalence rates of VTE in patients 
with COPD, ILD, CTD without ILD, and the general 
population were 2339, 2793, 1346, and 482 per 100,000 
individuals.
CTDs have been associated with an increased risk of 
PE and DVT development (Choi et al. 2013; Zoller et al. 
2012; Ramagopalan et  al. 2011; Matta et  al. 2009). The 
risk of DVT in CTD patients was approximately 2–3 
times higher than within the non-connective tissue disor-
der population (Choi et al. 2013; Zoller et al. 2012; Rama-
gopalan et  al. 2011; Matta et  al. 2009). In the present 
study, we evaluated all of the CTDs in the sample popu-
lation and discovered that the odds ratio for developing 
Table 2 Gender distribution of  the study population for  deep vein thrombosis, and  pulmonary embolism prevalence 
in the Korean sample population
Between January 2011 and December 2011. Summarized based on the diagnosis at the top of the list of the International Statistical Classification of Diseases and 
Related Health Problems, 10th edition (ICD-10) codes of respiratory diseases
ILD interstitial lung disease, COPD chronic obstructive pulmonary disease, CTD connective tissue disorder
Group Population Cases Prevalence 95 % CI Population Cases Prevalence 95 % CI
Men Women
Prevalence of deep vein thrombosis (1/100,000)
 General population 299,599 418 139.5 132.7–146.3 340,578 467 137.1 130.7–143.4
 COPD 8840 63 712.6 623.7–802.8 6846 37 540.6 451.3–628.3
 CTD 2009 15 746.6 529.2–895.9 5271 26 493.2 404.1–600.7
 ILD 571 2 350.2 103.2–598.5 288 3 1041.6 441.8–1634.2
Prevalence of pulmonary embolism (1/100,000)
 General population 299,599 319 106.4 100.5–112.4 340,578 406 119.2 113.3–125.1
 COPD 8840 110 1244.3 1127.4–1363.4 6846 76 1110.1 982.3–1235.3
 CTD 2009 9 447.9 285.3–569.7 5271 21 398.4 317.4–494.1
 ILD 571 12 2101.5 1503.9–2706.5 288 3 1041.6 441.8–1634.2
Table 3 Risk of deep vein thrombosis and pulmonary embolism prevalence in patients with chronic obstructive pulmo-
nary disease and connective tissue disorder
PE pulmonary embolism, CTD connective tissue disorder, COPD chronic obstructive pulmonary disease
Group Population Cases Prevalence 95 % CI Odds ratio 95 % CI
Deep vein thrombosis
 General population 640,177 885 138.2 133.6–142.8 Ref
 COPD 15,686 100 637.5 573.9–701.0 4.8 3.9–5.9
 CTD 7280 41 563.1 475.4–650.8 4.0 2.9–5.5
 ILD 859 5 582.0 322.5–841.6 4.41 1.8–10.6
Pulmonary embolism
 General population 640,177 725 113.2 109.0–117.4 Ref
 COPD 15,686 186 1185.7 1009.3–1272.2 11.3 9.6–13.2
 CTD 7280 30 412.0 337.0–487.1 3.61 2.5–5.2
 ILD 859 15 1746.2 1299.3–2193.1 16.39 9.7–27.4
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DVT in CTD patients is approximately 3.6–4.0 compared 
to the general population. The risk of developing DVT in 
CTD patients found in our study is slightly higher than 
that found by previous studies, which is partly influenced 
by selection bias from the sample population. However, 
the results of present study are comparable to a previous 
study (Ramagopalan et al. 2011).
ILDs have been associated with an increased risk of 
VTE development (Sprunger et  al. 2012; Hubbard et  al. 
2008; Sode et  al. 2010). The risk of DVT in ILD was 
approximately 2–3 times higher than that found within 
the control population (Hubbard et  al. 2008). The PE 
prevalence was higher in COPD patients (Tillie-Leblond 
et  al. 2006; Rizkallah et  al. 2009). In the present study, 
the risk of developing DVT or VTE in ILD and COPD 
patients was 4–6 times higher than that found within the 
control population.
The incidence of PE and DVT was similar in rheuma-
toid arthritis patients (Choi et  al. 2013). However, the 
prevalence of PE was approximately 2 times higher than 
that of DVT in the COPD population (Tillie-Leblond 
et al. 2006; Rutschmann et al. 2007). In the present study, 
the prevalence of DVT was higher than PE in the gen-
eral population and in CTD patients. In contrast to the 
general population and CTD patients, PE prevalence was 
2–3 times higher than DVT in COPD and ILD patients. 
There are two possibilities as to why there was a higher 
prevalence of PE than DVT in ILD and COPD patients. 
First, COPD and ILD patients have thrombogenic poten-
tial within the pulmonary circulation (Magee et al. 1988; 
Wright et al. 1992; Keane et al. 1997; Cosgrove et al. 2004; 
Renzoni et al. 2003; Sakao et al. 2006). Therefore, COPD 
and ILD patients have a chance to develop in situ throm-
bosis. Another possibility is that vascular bed changes 
may cause delayed resolution of or no resolution of PE 
from DVT. The pulmonary artery pressure is 2–3 times 
higher than the central venous pressure, which means 
that blood flow is faster in the pulmonary artery than in 
the peripheral vein. The pulmonary artery, from the pul-
monary circulation, accounted for 46 % of the total pul-
monary resistance (Brody et al. 1968). From this point of 
view, stagnation of blood in a lower extremity is different 
from that experienced by the pulmonary artery. The arte-
rial blood coagulation factor has a shorter length of stay 
in comparison to the venous coagulation factor, result-
ing in a relatively lower level of coagulation factors found 
in the artery. The exposure intensity of blood coagula-
tion factors in the pulmonary vein is assumed to be low 
in comparison to that found in the lower extremity vein. 
However, this physiologic phenomenon may be reversed 
by lung local factors (Keane et  al. 1997; Cosgrove et  al. 
2004; Renzoni et al. 2003; Sakao et al. 2006; Chaouat et al. 
2008; Behr and Ryu 2008). This may explain the discrep-
ancy of venous thrombosis prevalence between the lower 
extremity and pulmonary artery with or without the 
presence of chronic lung diseases.
The association between PE and infection is supported 
by several studies (Levi et  al. 2010; Levi 2004; D’Angelo 
et  al. 1988). Inflammatory condition may contribute 
the development of venous thrombosis. PE and DVT 
was significantly associated with COPD exacerbation as 
well as mortality (Gunen et  al. 2010). The odds ratio of 
PE ranged from 1.7 to 5.0 in inflammatory conditions 
(D’Angelo et al. 1988; Bucciarelli et al. 1999; Wells et al. 
2005). An inflammatory condition in conjunction with 
structural abnormalities may explain the high prevalence 
of pulmonary embolism in COPD and ILD.
In 2008, population-based statistics demonstrated 
that the PE and DVT incidence in the whole popula-
tion was 5.3 and 7.0 per 100,000 individuals, respectively 
(Jang et  al. 2011). When we confine this to those older 
than 40 years of age, DVT and PE reaches 13 and 24 per 
100,000 individuals, respectively. The incidence of PE 
based on the number of hospitalized adults was 100–200 
fold higher than that found in a population-based study 
in Korea, which is similar to the present study’s findings 
of PE prevalence (Choi et  al. 2012). This population-
based study used the whole population as the denomina-
tor. However, this HIRA data was based on individuals 
who visited a clinic at least once in the 2011 calendar 
year. This may lead to an overestimation of lung cancer 
prevalence in the HIRA data or an underestimation of 
venous thrombosis in the national statistics. Although 
there would be a discrepancy between this sample popu-
lation data and the national data, a comparison of the PE 
prevalence among the groups in the sample data would 
be possible.
The man-to-woman VTE cancer ratio was 1.0 in those 
within the background population. The ratios of COPD, 
ILD, and CTD were 1.1, 1.2, and 1.0, respectively. There 
Fig. 1 Deep vein thrombosis (DVT) and pulmonary embolism (PE) 
prevalence rates between the groups. COPD chronic obstructive 
pulmonary disease, ILD interstitial lung disease, CTD connective tissue 
disorder. Gray bar denotes DVT and black bar denotes PE
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was no significant difference between the groups. We 
suspect that the prevalence of VTE is less influenced by 
sex even in patients with CTDs.
The HIRA database provided limited available patient 
data regarding age, sex, year, diagnostic code, and medi-
cation code. Therefore, we could not accurately vali-
date patients by identification or exclusion of definition 
through review of the source medical records. The sever-
ity of patients with venous thromboembolism was not 
evaluated due to the limitation of access to the individ-
ual medical records. However, this large-scale data may 
provide new insights of PE prevalence in patients with 
COPD and ILD.
In conclusion, our study suggests that the PE preva-
lence in relation to DVT was significantly higher in 
patients with COPD or ILD than in patients with CTD 
without ILD or within the general population. Further-
more, our findings suggest that local inflammatory and 
physiologic factors may contribute to the development of 
PE.
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